Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PYXS
Strong SellHot AirPyxis Oncology, Inc. · Healthcare · United States · $269M · Avg Vol: $4M/d
15
StockRankGet insider-trade alerts
Q
11
V
21
M
62
P/E (TTM)
—
ROE
-179.1%
D/E
1.6x
Dividend %
—
COMPANY DESCRIPTION
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 16.1M | 13.9M | -14.2% | 11.0M | 19.4K | 2.8M | -55.2% |
| EPS | -3.65 | -1.85 | -1.32 | -1.28 | — | -1.33 | -1.22 | -1.13 | — |
| Shares | 35.0M | 44.8M | 60.0M | 62.7M | +79.3% | 83.4M | — | — | — |
| Debt | 18.9M | 21.3M | 20.2M | 18.7M | -0.4% | 17.8M | — | — | — |
| Equity | 160.8M | 125.7M | 120.8M | 53.4M | -30.8% | — | — | — | — |
| Op CF | -89.3M | -70.7M | -57.7M | -63.5M | — | -67.9M | — | — | — |
| Inv CF | -6.4M | -104.8M | 8.2M | 58.9M | — | — | — | — | — |
| Fin CF | 0.2M | 5.9M | 59.3M | 0.6M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+13.9%
SMA 50SMA 200
Close
$3.27
RSI (14)
53.3
52W High
$5.55
From 52W High
0.6%
SCORE BREAKDOWN
Quality
11
ROIC
-122.0%5.1
ROE
-179.1%4.9
GP/Assets
9.5%24.7
Op. Margin
-812.7%7.9
FCF/Assets
-69.4%4.4
Piotroski
25.9
Int. Cover
—N/A
D/E Ratio
1.56x7.8
Current Ratio
1.34x21.2
Value
21
P/E (TTM)
—N/A
EV/EBITDA
-3.3x25.0
P/FCF
—N/A
P/B
21.6x5.0
P/S
29.4x12.8
Div Yield
—N/A
Momentum
62
52W High %
59%35.1
RS 6M
97%96.9
SMA 50/200
1.33x94.4
EPS Rev 4W
+6.4%85.9
EPS Rev 12W
—N/A
EPS Improve
+15%31.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$269M
P/E (Forward)
-3.4x
Gross Margin
78.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PYXS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc.(you) | $269M | 15 | Strong Sell |
| SION | Sionna Therapeutics, Inc. | $265M | 14 | Strong Sell |
| ELDN | Eledon Pharmaceuticals, Inc. | $260M | 15 | Strong Sell |
| MGNX | MacroGenics, Inc. | $263M | 17 | Strong Sell |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $233M | 14 | Strong Sell |
| IVVD | Invivyd, Inc. | $284M | 12 | Strong Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 17 | Strong Sell |
| TTRX | Turn Therapeutics Inc. | $299M | 13 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 12 | Strong Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 17 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%